Baidu
map

Lenzilumab治疗COVID-19住院患者,即将开展III期临床

2021-01-31 Allan MedSci原创

生物制药公司Humanigen近日宣布,已完成Lenzilumab治疗COVID-19住院患者的III期研究入组工作。该公司预计将于2021年3月公布主要临床数据。

生物制药公司Humanigen近日宣布,已完成Lenzilumab治疗COVID-19住院患者的III期研究入组工作。该公司预计将于2021年3月公布主要临床数据。

这项III期随机、双盲、安慰剂对照临床试验招募了520例患者,其主要目标是确定lenzilumab能否缓解免疫介导的细胞因子释放综合征(CRS)并改善COVID-19住院和低氧患者的无呼吸机生存。

Humanigen首席执行官Cameron Durrant博士说:“完成这项III期研究的入组是lenzilumab临床开发的重要里程碑。与疫苗一起使用的药物是治疗COVID-19的重要工具。我们感谢试验参与者、研究人员和医疗保健专业人员在促进lenzilumab的方面所做出的贡献”。

Lenzilumab是一种抗人类粒细胞巨噬细胞集落刺激因子(GM-CSF)单克隆抗体,旨在预防和治疗细胞因子风暴,这种并发症被认为是引起急性呼吸窘迫综合征(ARDS)的原因,并可能导致某些COVID-19患者死亡。数据显示,近90%的COVID-19住院患者有罹患细胞因子风暴的风险。

 

原始出处:

https://www.firstwordpharma.com/node/1795971?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1653155, encodeId=64ba1653155ce, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Sep 29 11:27:06 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916397, encodeId=d18e191639e7b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Apr 27 22:27:06 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912530, encodeId=d85e1912530ba, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jun 13 17:27:06 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524921, encodeId=14471524921e8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue Feb 02 07:27:06 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594857, encodeId=b79b159485e53, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Feb 02 07:27:06 CST 2021, time=2021-02-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1653155, encodeId=64ba1653155ce, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Sep 29 11:27:06 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916397, encodeId=d18e191639e7b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Apr 27 22:27:06 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912530, encodeId=d85e1912530ba, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jun 13 17:27:06 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524921, encodeId=14471524921e8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue Feb 02 07:27:06 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594857, encodeId=b79b159485e53, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Feb 02 07:27:06 CST 2021, time=2021-02-02, status=1, ipAttribution=)]
    2021-04-27 juliusluan78
  3. [GetPortalCommentsPageByObjectIdResponse(id=1653155, encodeId=64ba1653155ce, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Sep 29 11:27:06 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916397, encodeId=d18e191639e7b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Apr 27 22:27:06 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912530, encodeId=d85e1912530ba, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jun 13 17:27:06 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524921, encodeId=14471524921e8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue Feb 02 07:27:06 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594857, encodeId=b79b159485e53, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Feb 02 07:27:06 CST 2021, time=2021-02-02, status=1, ipAttribution=)]
    2021-06-13 snf701207
  4. [GetPortalCommentsPageByObjectIdResponse(id=1653155, encodeId=64ba1653155ce, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Sep 29 11:27:06 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916397, encodeId=d18e191639e7b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Apr 27 22:27:06 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912530, encodeId=d85e1912530ba, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jun 13 17:27:06 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524921, encodeId=14471524921e8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue Feb 02 07:27:06 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594857, encodeId=b79b159485e53, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Feb 02 07:27:06 CST 2021, time=2021-02-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1653155, encodeId=64ba1653155ce, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Sep 29 11:27:06 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916397, encodeId=d18e191639e7b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Apr 27 22:27:06 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912530, encodeId=d85e1912530ba, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jun 13 17:27:06 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524921, encodeId=14471524921e8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue Feb 02 07:27:06 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594857, encodeId=b79b159485e53, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Feb 02 07:27:06 CST 2021, time=2021-02-02, status=1, ipAttribution=)]

相关资讯

Incyte启动JAK抑制剂芦可替尼治疗COVID-19相关细胞因子风暴III期研究

4月17日,Incyte宣布启动一项代号为RUXCOVID的全球性、随机、双盲、安慰剂对照III期临床试验,计划在全球招募约400名患者,为期29天,主要评估Jakafi(芦可替尼)联合标准护理(So

综述:新冠肺炎的炎症风暴到底有何特殊之处?

新型冠状病毒(SARS-CoV-2)自入侵我国以来,给我国乃至世界各国造成了巨大的经济损失,也严重威胁着世界各国人民的生命安全。之前的推送已经对免疫系统中各个组分在病毒感染中的作用进行了概述,本次我们

JAK抑制剂ruxolitinib治疗重度COVID-19患者:正在进行评估

Incyte和诺华制药近日宣布,两家公司计划启动一项III期临床试验(RUXCOVID研究),以评估ruxolitinib联合标准疗法治疗COVID-19相关细胞因子风暴的有效性和安全性。

IL-6试验令人失望后,诺华将测试IL-1单抗canakinumab用于抵抗新冠COVID-19的细胞因子风暴

新型冠状病毒COVID-19患者体内的炎症因子IL-1β水平显着升高。

QRB Discovery :MIT开发出新蛋白,或可阻止COVID-19患者出现细胞因子风暴

Covid-19的主要特征之一是在严重情况下可能会发生过度的免疫反应。这种免疫过度反应的爆发,也称为细胞因子风暴,会损害肺部并可能致命。细胞因子风暴始终是冠状病毒及其他严重感染患者疾病进展及死亡的重要

Lenzilumab预防COVID-19“细胞因子风暴”:已开展III期临床试验

Humanigen是一家临床阶段的生物制药公司,致力于通过lenzilumab预防和治疗称为“细胞因子风暴”的免疫反应过度。

拓展阅读

Lenzilumab 治疗 COVID-19 住院患者,未达到主要终点

FDA 已经拒绝了该公司寻求紧急使用该疗法治疗新住院 COVID-19 患者的请求。美国监管机构确定,它无法得出 lenzilumab 的潜在益处超过潜在风险的结论。

Lenzilumab预防或治疗与CAR-T细胞疗法相关细胞因子风暴和神经毒性

临床阶段生物制药公司Humanigen今天宣布,美国专利商标局已向公司授予一项专利,该专利用于使用lenzilumab预防或治疗接受嵌合抗原受体T(CAR-T)细胞治疗的患者的细胞因子风暴和神经毒性。

Lenzilumab治疗COVID-19住院患者的III期临床:已取得阳性中期数据

与目前的标准护理(SOC)相比,lenzilumab组中观察到的康复估计多了37%。

Lenzilumab预防COVID-19“细胞因子风暴”:已开展III期临床试验

Humanigen是一家临床阶段的生物制药公司,致力于通过lenzilumab预防和治疗称为“细胞因子风暴”的免疫反应过度。

美国国立卫生研究院选择Lenzilumab进行COVID-19的大效应试验(BET)

美国国立卫生研究院(NIH)旗下的国家过敏和传染病研究所(NIAID)将选择Humanigen的lenzilumab进行COVID-19的大效应试验(BET)。

Baidu
map
Baidu
map
Baidu
map